Lumida
/ABUS
⌘K
Arbutus Biopharma Corp

Arbutus Biopharma Corp

ABUS
$5.12USD+0.00%+0.00 today

MARKET CAP

1.0B

P/E (TTM)

6.2x

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$4
$5

AI Summary

Stalk
Buy NowMedium

ABUS remains in a Stage 2 advance with price tightly consolidating above rising EMAs. The Devil’s Bargain continuation pattern highlights persistent buying pressure, and momentum orientation supports participation on shallow pullbacks. Despite overbought readings and proximity to recent highs, entry near the 9- and 20-day EMA zone offers favorable risk–reward for continued upside extension.

  • Phase IIa data reveal 33%–67% undetectable HBsAg rates
  • $131M cash secures runway through Q4 2026 vs $63–67M burn
  • Projected $63–67M cash burn in 2024 risks runway
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$11.0M$39.0M$18.1M$6.2M$14.1M
YoY %+58.9%+255.1%-53.5%-66.0%+128.2%
P / Sales37.6x8.6x23.7x98.4x65.4x
EV / Sales30.9x9.3x24.4x98.0x65.4x
Gross Profit, Adj.$11.0M$39.0M$18.1M$6.2M$14.1M
YoY %+58.9%+255.1%-53.5%-66.0%+128.2%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit30.9x9.3x24.4x98.0x65.4x
EBITDA, Adj.$-69.9M$-64.0M$-76.7M$-71.2M$-24.9M
YoY %-26.4%+8.4%-19.8%+7.1%+65.1%
Margin %-636.1%-164.1%-422.8%-1154.1%-176.5%
EV / EBITDA-4.9x-5.7x-5.8x-8.5x-37.1x
EBIT$-73.5M$-65.5M$-78.1M$-76.3M$-38.2M
YoY %-27.2%+11.0%-19.3%+2.3%+50.0%
Margin %-669.1%-167.8%-430.5%-1236.7%-271.0%
EV / EBIT-4.6x-5.6x-5.7x-7.9x-24.2x
Net Income$-88.4M$-69.5M$-72.8M$-69.9M$-33.5M
YoY %-16.5%+21.4%-4.9%+4.0%+52.1%
Net Margin-804.4%-178.0%-401.6%-1133.0%-237.9%
EPS (GAAP)-$0.83-$0.46-$0.44-$0.38-$0.17
YoY %+17.0%+44.6%+4.3%+13.6%+55.3%